Share This Page
aspirin; carisoprodol; codeine phosphate - Profile
✉ Email this page to a colleague
What are the generic sources for aspirin; carisoprodol; codeine phosphate and what is the scope of patent protection?
Aspirin; carisoprodol; codeine phosphate
is the generic ingredient in two branded drugs marketed by Ingenus Pharms Nj, Oxford Pharms, Sandoz, and Meda Pharms, and is included in four NDAs. Additional information is available in the individual branded drug profile pages.Summary for aspirin; carisoprodol; codeine phosphate
| US Patents: | 0 |
| Tradenames: | 2 |
| Applicants: | 4 |
| NDAs: | 4 |
US Patents and Regulatory Information for aspirin; carisoprodol; codeine phosphate
Expired US Patents for aspirin; carisoprodol; codeine phosphate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Meda Pharms | SOMA COMPOUND W/ CODEINE | aspirin; carisoprodol; codeine phosphate | TABLET;ORAL | 012366-002 | Jul 11, 1983 | ⤷ Get Started Free | ⤷ Get Started Free |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Pharmaceutical Compound Fundamentals Analysis: Aspirin, Carisoprodol, and Codeine Phosphate
This analysis examines the patent landscape, market dynamics, and regulatory considerations for aspirin, carisoprodol, and codeine phosphate. It provides data-driven insights for R&D and investment decisions.
What is the current patent status for these compounds?
The patent status for aspirin, carisoprodol, and codeine phosphate varies significantly due to their age and the evolution of patent law.
Aspirin (Acetylsalicylic Acid)
Aspirin, first synthesized in 1853 and patented in its medicinal form by Bayer AG in 1899 (US Patent 644,077), is long off-patent. Its composition of matter patent has expired.
- Composition of Matter Patent: Expired.
- Formulation Patents: While the core molecule is unpatentable, patents can exist for novel formulations, delivery systems, or specific uses. However, many such patents for well-established formulations would have expired or are unlikely to provide significant market exclusivity.
- Manufacturing Process Patents: Older process patents are expired. Newer, more efficient, or environmentally friendly manufacturing processes might have been patented.
Carisoprodol
Carisoprodol, originally patented by Wallace Laboratories in 1959, also has its composition of matter patents expired.
- Composition of Matter Patent: Expired.
- Formulation and Use Patents: As with aspirin, any patents relating to specific formulations, combination therapies, or new indications for carisoprodol would have expired or are unlikely to offer robust market protection.
- Manufacturing Process Patents: Early manufacturing patents are expired. Development of novel synthetic routes could theoretically be patented if they meet the criteria for novelty and non-obviousness, but this is less common for established generics.
Codeine Phosphate
Codeine phosphate is a salt of codeine, a naturally occurring opiate alkaloid. Codeine itself was recognized and used medicinally long before modern patent systems.
- Composition of Matter Patent: Expired for codeine and its basic salts.
- Formulation Patents: Patents may exist for specific extended-release formulations, combination products (e.g., with acetaminophen), or novel delivery mechanisms for codeine phosphate. However, the underlying active pharmaceutical ingredient (API) is generic.
- Manufacturing Process Patents: Initial patents for isolating codeine from opium or for synthesizing it are expired.
What are the market dynamics and competitive landscape for these drugs?
The market dynamics are characterized by generic competition, regulatory pressures, and evolving therapeutic guidelines.
Aspirin
Aspirin is a high-volume, low-cost generic drug. Its primary markets are:
-
Analgesia and Antipyresis: Used for pain and fever relief.
-
Antiplatelet Therapy: A cornerstone in cardiovascular disease prevention (low-dose aspirin).
-
Market Size: Difficult to precisely quantify due to its widespread availability and use across numerous markets. Global sales of products containing aspirin as the sole API would be in the billions of dollars annually, with the majority of sales being generic.
-
Key Players: Numerous generic manufacturers globally, including Teva Pharmaceutical Industries, Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, and numerous smaller regional players. Brand-name products like Bayer's Aspirin remain but represent a smaller share of the total volume.
-
Competition: Intense, price-driven competition among generic manufacturers. Differentiation occurs through branding, formulation (e.g., enteric-coated, effervescent), and distribution channels.
Carisoprodol
Carisoprodol, marketed under brand names like Soma, is primarily used as a skeletal muscle relaxant. Its market has been significantly impacted by regulatory scrutiny due to abuse potential.
- Market Size: Historically, the market for carisoprodol was substantial, with global sales in the hundreds of millions of dollars. However, its market has contracted due to rescheduling and restrictions. The U.S. market alone was estimated to be in the low hundreds of millions before significant regulatory actions.
- Key Players: Original manufacturer (Endo International plc, which acquired the brand rights) and generic manufacturers.
- Competition: Primarily generic competition. However, the therapeutic landscape has shifted with the increased availability of alternative muscle relaxants and concerns about carisoprodol's efficacy and abuse potential.
Codeine Phosphate
Codeine phosphate is used for pain relief and as an antitussive. It is often found in combination products.
- Market Size: The market for codeine-containing products is significant but fragmented. Pure codeine phosphate products compete with a vast array of combination analgesics (e.g., with acetaminophen, ibuprofen). The global market for prescription pain relievers, where codeine plays a role, is in the tens of billions of dollars annually. Codeine phosphate as a standalone API or in basic formulations contributes a fraction of this.
- Key Players: Pharmaceutical companies producing both branded and generic versions of codeine phosphate and its combination products. Examples include Hikma Pharmaceuticals, Rhodes Pharmaceuticals (an Amneal Pharmaceuticals company), and numerous others.
- Competition: High. Competition exists from other opioids, non-opioid analgesics, and alternative antitussives. Combination products face competition from other combinations and single-agent therapies.
What is the regulatory status and outlook for these compounds?
Regulatory actions, particularly concerning controlled substances and drug safety, significantly shape the market access and commercial viability of these drugs.
Aspirin
Aspirin is generally considered a safe and well-established over-the-counter (OTC) medication.
- Classification: OTC in most markets for standard doses. Prescription status for higher doses or specific indications (e.g., cardiovascular prevention).
- Regulatory Oversight: Governed by general drug safety and efficacy regulations (e.g., FDA in the U.S., EMA in Europe). Focus is on labeling, warnings (e.g., Reye's syndrome in children), and manufacturing standards.
- Outlook: Stable. Continued widespread use for its established indications. Potential for minor regulatory updates related to warnings or formulation requirements.
Carisoprodol
Carisoprodol has faced increasing regulatory scrutiny due to its potential for abuse and dependence.
- Classification: Scheduled controlled substance in many jurisdictions. In the U.S., it is a Schedule IV controlled substance under the Controlled Substances Act (CSA). This classification has led to stricter prescribing, dispensing, and manufacturing regulations.
- Regulatory Actions:
- DEA Scheduling: Implemented in the U.S. in March 2014.
- Marketing Restrictions: Previous marketing claims have been challenged by regulatory bodies.
- Prescription Monitoring Programs: Integration into state and national prescription drug monitoring programs.
- Outlook: Challenging. The trend is towards reduced prescribing and greater caution due to abuse potential. Its use may be increasingly limited to short-term treatment for specific indications, with a preference for alternative therapies. Manufacturers face stricter DEA quotas and compliance burdens.
Codeine Phosphate
Codeine phosphate is a controlled substance with varying classifications and increasing regulatory attention due to its opioid nature.
- Classification: Controlled substance in most countries. In the U.S., it is typically classified as a Schedule II, III, or V controlled substance depending on the concentration and whether it is in a combination product. For example, pure codeine phosphate is Schedule II, while many combination products are Schedule III.
- Regulatory Actions:
- Opioid Crisis Response: Codeine, as an opioid, is subject to broader regulatory efforts aimed at curbing opioid addiction and misuse.
- Prescribing Guidelines: Increased emphasis on cautious prescribing, alternative pain management strategies, and prescription limits.
- DEA Quotas: Manufacturers are subject to annual production quotas set by the DEA.
- Labeling and Warning Requirements: Enhanced warnings regarding addiction potential, overdose, and respiratory depression.
- Outlook: Complex. Demand for effective pain relief persists, but regulatory pressure on opioids will continue to shape its use. Combination products are under particular scrutiny, with a trend towards limiting their availability or favoring formulations with lower abuse potential. Antitussive use may also face pressure from non-opioid alternatives.
What are the scientific and therapeutic considerations?
Understanding the pharmacological profiles and clinical utility is critical for evaluating long-term relevance.
Aspirin
- Mechanism of Action: Irreversible inhibitor of cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis. Antiplatelet effect is due to inhibition of COX-1 in platelets, preventing thromboxane A2 formation.
- Therapeutic Uses: Analgesic, antipyretic, anti-inflammatory (at higher doses), antiplatelet agent.
- Safety Profile: Gastrointestinal bleeding, ulcers, tinnitus, hypersensitivity reactions. Risk of Reye's syndrome in children and adolescents with viral infections.
- Scientific Relevance: While its basic mechanism is well-understood, research continues on optimizing its use in cardiovascular prevention and exploring novel anti-inflammatory applications.
Carisoprodol
- Mechanism of Action: Exact mechanism is not fully elucidated. It is metabolized to meprobamate, a carbamate derivative with anxiolytic and sedative properties. Its muscle relaxant effects are thought to be related to central nervous system depression rather than direct action on skeletal muscle.
- Therapeutic Uses: Skeletal muscle spasms.
- Safety Profile: Sedation, dizziness, drowsiness, dependence, abuse potential, withdrawal symptoms. Respiratory depression when combined with other CNS depressants.
- Scientific Relevance: Limited ongoing research into novel therapeutic uses due to safety concerns and availability of alternatives. Focus is on risk mitigation and understanding abuse patterns.
Codeine Phosphate
- Mechanism of Action: A weak opioid agonist. It is metabolized in the liver by CYP2D6 to morphine, which is the primary active metabolite responsible for analgesia. It also acts on opioid receptors directly to a lesser extent.
- Therapeutic Uses: Mild to moderate pain, cough suppression.
- Safety Profile: Constipation, nausea, vomiting, dizziness, drowsiness, respiratory depression, addiction, dependence, withdrawal. Poor metabolizers of CYP2D6 may not achieve adequate pain relief. Ultra-rapid metabolizers are at higher risk of toxicity.
- Scientific Relevance: Research focuses on understanding inter-individual variability in CYP2D6 metabolism, developing safer opioid alternatives, and strategies to mitigate addiction and overdose risks.
What are potential R&D and investment strategies?
Given the mature nature of these compounds, R&D and investment opportunities lie in specific niches and strategic approaches.
Aspirin
- Niche Formulations: Development of novel drug delivery systems (e.g., ultra-fast dissolving, targeted release) for specific patient populations or indications.
- Combination Therapies: Investigating synergistic effects with other APIs for enhanced efficacy or reduced side effects in pain management or cardiovascular disease.
- Biomarker Identification: Research into patient stratification for optimal response to aspirin therapy, particularly in cardiovascular prevention.
- Investment Focus: Companies with efficient, high-volume generic manufacturing capabilities. Companies exploring novel delivery platforms for established APIs.
Carisoprodol
- Limited R&D: Due to its controlled substance status and abuse potential, significant investment in novel R&D for carisoprodol is unlikely. The focus would be on managing its existing market.
- Market Optimization: For companies holding generic rights, strategies would involve efficient supply chain management and targeted marketing to prescribers who still opt for the drug within regulatory guidelines.
- Investment Focus: Companies with established generic manufacturing and robust compliance systems that can navigate stringent DEA regulations. Acquiring portfolios of controlled substances from companies divesting these assets.
Codeine Phosphate
- Safer Formulations: Development of abuse-deterrent formulations of codeine or its combinations.
- Combination Product Innovation: Creating novel combinations with non-opioid analgesics or other agents to improve efficacy and reduce opioid reliance.
- Targeted Pain Management: Research into genetic testing (e.g., CYP2D6 phenotyping) to personalize codeine therapy or identify patients who would benefit more from alternative analgesics.
- Investment Focus: Companies with expertise in pain management and the development of abuse-deterrent technologies. Manufacturers with strong opioid compliance programs and a strategic approach to managing controlled substances in the current regulatory climate.
Key Takeaways
- Aspirin is a foundational generic with enduring therapeutic value, primarily facing market competition rather than patent or significant regulatory hurdles. Opportunities lie in formulation innovation and high-volume manufacturing.
- Carisoprodol has seen its market significantly constrained by its classification as a controlled substance and associated abuse potential, leading to strict regulation and a contracting market. Investment is limited to companies with specialized expertise in controlled substance handling.
- Codeine Phosphate operates within the complex landscape of opioid regulation. While demand for pain relief persists, regulatory pressures are driving a shift towards safer alternatives and abuse-deterrent formulations. Companies must navigate stringent controlled substance regulations and evolving prescribing guidelines.
Frequently Asked Questions
Are there any remaining patents that could offer market exclusivity for aspirin?
While the composition of matter patent for aspirin has long expired, patents could theoretically exist for novel and non-obvious formulations, delivery systems, or specific therapeutic uses that are not yet publicly known or utilized. However, due to its ubiquity, such patents are unlikely to provide broad or long-lasting market exclusivity.
What are the primary reasons for carisoprodol's scheduling as a controlled substance?
Carisoprodol was scheduled primarily due to its potential for abuse, dependence, and the significant risks associated with its misuse, particularly when combined with other central nervous system depressants. Its metabolite, meprobamate, also has a known potential for abuse.
How does the CYP2D6 enzyme affect codeine's efficacy and safety?
Codeine is a prodrug that requires metabolism by the CYP2D6 enzyme in the liver to convert into morphine, its primary active analgesic metabolite. Individuals with a genetic deficiency in CYP2D6 activity (poor metabolizers) may not experience adequate pain relief from codeine. Conversely, individuals who are ultra-rapid metabolizers can convert codeine to morphine too quickly, increasing the risk of opioid toxicity and side effects.
What are the main therapeutic differences between aspirin, carisoprodol, and codeine phosphate?
Aspirin is primarily an analgesic, antipyretic, anti-inflammatory, and antiplatelet agent. Carisoprodol is a skeletal muscle relaxant. Codeine phosphate is a weak opioid analgesic and antitussive. Their mechanisms of action and primary indications are distinct.
What is the trend in regulatory oversight for opioid-based pain medications like codeine phosphate?
The global trend is towards increased regulatory oversight and caution regarding opioid-based medications. This includes stricter prescribing guidelines, efforts to reduce overall opioid prescribing, enhanced monitoring programs, and a push for the development and adoption of non-opioid pain management strategies and abuse-deterrent formulations.
Citations
- U.S. Patent and Trademark Office. (1899). U.S. Patent 644,077. Retrieved from USPTO database.
- World Intellectual Property Organization. (n.d.). Codeine. Retrieved from WIPO Lex database.
- Food and Drug Administration. (n.d.). Controlled Substances Act. Retrieved from FDA website.
- Drug Enforcement Administration. (n.d.). Schedules of Controlled Substances. Retrieved from DEA website.
More… ↓
